Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1996 Oct 1;155(7):962–965.

Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis.

K Siminoski 1, R G Josse 1
PMCID: PMC1335462  PMID: 8837547

Abstract

OBJECTIVE: To describe potential therapeutic uses of calcitonin in the prevention and treatment of osteoporosis. OPTIONS: Parenterally and intranasally administered calcitonin (eel, salmon or human). OUTCOMES: Fracture, fracture pain and loss of bone mineral density in osteoporosis; increased bone mass, prevention of fractures, reduction of pain and improved quality of life associated with calcitonin treatment. EVIDENCE: Relevant clinical studies and reports were examined, with an emphasis on recent randomized, placebo-controlled trials. In vitro and in vivo studies of osteoclast activity were also considered. VALUES: Reducing fractures and fracture pain, increasing bone mineral density and minimizing side effects of treatment were given a high value. BENEFITS, HARMS AND COSTS: Calcitonin reduces acute pain associated with osteoporotic fractures and has been found useful in treating chronic back pain following vertebral fractures in spinal osteoporosis. It can prevent bone loss and may be effective in preventing fractures. Side effects are dose related and generally mild; they include gastrointestinal, vascular and dermatologic conditions that can be treated symptomatically or by varying the dosage. Side effects are much rarer with nasal administration than with injection. True allergic reactions are rare. RECOMMENDATIONS: Calcitonin in both intramuscular and intranasal forms can reduce the pain of acute osteoporotic vertebral fractures and may be effective in treating that associated with chronic vertebral osteoporotic fractures. Calcitonin may also prevent postmenopausal bone loss and increase bone density in those with established osteoporosis. Current evidence for long-term prevention of fractures is limited and does not support the use of calcitonin as a first-line treatment for established osteoporosis. Most side effects can be avoided with nasal administration. Further trials are needed to assess fracture prevention and effective dose ranges for treating pain and increasing bone mineral density and to determine the long-term efficacy of calcitonin in secondary osteoporosis, in premenopausal women, in men and in elderly people.

Full text

PDF
965

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Civitelli R., Gonnelli S., Zacchei F., Bigazzi S., Vattimo A., Avioli L. V., Gennari C. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest. 1988 Oct;82(4):1268–1274. doi: 10.1172/JCI113725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fioretti P., Gambacciani M., Taponeco F., Melis G. B., Capelli N., Spinetti A. Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women. Maturitas. 1992 Dec;15(3):225–232. doi: 10.1016/0378-5122(92)90206-j. [DOI] [PubMed] [Google Scholar]
  3. Gennari C., Agnusdei D., Montagnani M., Gonnelli S., Civitelli R. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int. 1992 Apr;50(4):381–383. doi: 10.1007/BF00301638. [DOI] [PubMed] [Google Scholar]
  4. Ljunghall S., Gärdsell P., Johnell O., Larsson K., Lindh E., Obrant K., Sernbo I. Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study. Calcif Tissue Int. 1991 Jul;49(1):17–19. doi: 10.1007/BF02555897. [DOI] [PubMed] [Google Scholar]
  5. Luengo M., Pons F., Martinez de Osaba M. J., Picado C. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax. 1994 Nov;49(11):1099–1102. doi: 10.1136/thx.49.11.1099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Lyritis G. P., Tsakalakos N., Magiasis B., Karachalios T., Yiatzides A., Tsekoura M. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int. 1991 Dec;49(6):369–372. doi: 10.1007/BF02555844. [DOI] [PubMed] [Google Scholar]
  7. MacIntyre I., Stevenson J. C., Whitehead M. I., Wimalawansa S. J., Banks L. M., Healy M. J. Calcitonin for prevention of postmenopausal bone loss. Lancet. 1988 Apr 23;1(8591):900–902. doi: 10.1016/s0140-6736(88)91712-6. [DOI] [PubMed] [Google Scholar]
  8. Mazzuoli G. F., Passeri M., Gennari C., Minisola S., Antonelli R., Valtorta C., Palummeri E., Cervellin G. F., Gonnelli S., Francini G. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int. 1986 Jan;38(1):3–8. doi: 10.1007/BF02556587. [DOI] [PubMed] [Google Scholar]
  9. Meschia M., Brincat M., Barbacini P., Crossignani P. G., Albisetti W. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int. 1993 Jul;53(1):17–20. doi: 10.1007/BF01352009. [DOI] [PubMed] [Google Scholar]
  10. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int. 1994 Aug;55(2):82–86. doi: 10.1007/BF00297179. [DOI] [PubMed] [Google Scholar]
  11. Overgaard K., Hansen M. A., Jensen S. B., Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. 1992 Sep 5;305(6853):556–561. doi: 10.1136/bmj.305.6853.556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Overgaard K., Riis B. J., Christiansen C., Hansen M. A. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ. 1989 Aug 19;299(6697):477–479. doi: 10.1136/bmj.299.6697.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Overgaard K., Riis B. J., Christiansen C., Pødenphant J., Johansen J. S. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) 1989 Apr;30(4):435–442. doi: 10.1111/j.1365-2265.1989.tb00443.x. [DOI] [PubMed] [Google Scholar]
  14. Palmieri G. M., Pitcock J. A., Brown P., Karas J. G., Roen L. J. Effect of calcitonin and vitamin D in osteoporosis. Calcif Tissue Int. 1989 Sep;45(3):137–141. doi: 10.1007/BF02556055. [DOI] [PubMed] [Google Scholar]
  15. Pun K. K., Chan L. W. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther. 1989 Mar-Apr;11(2):205–209. [PubMed] [Google Scholar]
  16. Reginster J. Y., Denis D., Albert A., Deroisy R., Lecart M. P., Fontaine M. A., Lambelin P., Franchimont P. 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet. 1987 Dec 26;2(8574):1481–1483. doi: 10.1016/s0140-6736(87)92619-5. [DOI] [PubMed] [Google Scholar]
  17. Reginster J. Y., Denis D., Deroisy R., Lecart M. P., De Longueville M., Zegels B., Sarlet N., Noirfalisse P., Franchimont P. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res. 1994 Jan;9(1):69–73. doi: 10.1002/jbmr.5650090110. [DOI] [PubMed] [Google Scholar]
  18. Reginster J. Y., Deroisy R., Lecart M. P., Sarlet N., Zegels B., Jupsin I., de Longueville M., Franchimont P. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med. 1995 May;98(5):452–458. doi: 10.1016/S0002-9343(99)80344-1. [DOI] [PubMed] [Google Scholar]
  19. Rico H., Hernandez E. R., Revilla M., Gómez-Castresana F. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner. 1992 Feb;16(2):131–138. doi: 10.1016/0169-6009(92)90883-f. [DOI] [PubMed] [Google Scholar]
  20. Ringe J. D., Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol. 1987;33(1):35–39. doi: 10.1007/BF00610377. [DOI] [PubMed] [Google Scholar]
  21. Thamsborg G., Storm T. L., Sykulski R., Brinch E., Nielsen H. K., Sørensen O. H. Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int. 1991 May;48(5):302–307. doi: 10.1007/BF02556148. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES